For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...
A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in approving crucial clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback